GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma

• S. Gallego ^[2] ; D. Bernabeu ^[1] ; M. Garrido-Pontnou ^[3] ; G. Guillen ^[4] ; N. Hindi ^[5] ; A. Juan-Ribelles ^[6] ; C. Márquez ^[7] ; C. Mata ^[8] ; J. Orcajo ^[9] ; G. Ramírez ^[7] ; M. Ramos ^[10] ; C. Romagosa ^[11] ; D. Ruano ^[12] ; P. Rubio ^[13] ; R. Vergés ^[14] ; C. Valverde ^[10]
  1. [1] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  2. [2] Pediatric Oncology and Hematology, Vall D’Hebron University Hospital, Pº Vall d’Hebron 119-129, 08035, Barcelona, Spain
  3. [3] Pediatric and Perinatal Pathology Unit, Pathology Department, Vall D’Hebron University Hospital (Barcelona), Barcelona, Spain
  4. [4] Surgical Oncology Unit, Pediatric Surgery Department, Vall D’Hebron University Hospital (Barcelona), Barcelona, Spain
  5. [5] Sarcoma Unit, University Hospital Fundación Jimenez Díaz (Madrid), Madrid, Spain
  6. [6] Pediatric Oncology and Hematology, University Hospital La Fe (Valencia), Valencia, Spain
  7. [7] Pediatric Oncology and Hematology, Pediatric Hospital Virgen del Rocío (Sevilla), Sevilla, Spain
  8. [8] Pediatric Oncology and Hematology, Gregorio Marañón University Hospital (Madrid), Madrid, Spain
  9. [9] Nuclear Medicine Department, Gregorio Marañón University Hospital (Madrid), Madrid, Spain
  10. [10] Radiotherapy Department, Vall D’Hebron University Hospital (Barcelona), Barcelona, Spain
  11. [11] Pathology Department, Vall D’Hebron University Hospital (Barcelona), Barcelona, Spain
  12. [12] Pediatric Oncology and Hematology, Hospital Niño Jesús (Madrid), Madrid, Spain
  13. [13] Pediatric Oncology and Hematology, University Hospital La Paz (Madrid), Madrid, Spain
  14. [14] Medical Oncology, Vall D’Hebron University Hospital, Pº Vall d’Hebron 119-129, 08035, Barcelona, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 12 (Diciembre), 2021, págs. 2460-2473
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma (STS) in children and adolescents. In Spain the annual incidence is 4.4 cases per million children < 14 years. It is an uncommon neoplasm in adults, but 40% of RMS are diagnosed in patients over 20 years of age, representing 1% of all STS in this age group. RMS can appear anywhere in the body, with some sites more frequently affected including head and neck, genitourinary system and limbs. Assessment of a patient with suspicion of RMS includes imaging studies (MRI, CT, PET-CT) and biopsy. All patients with RMS should receive chemotherapy, either at diagnosis in advanced or metastatic stages, or after initial resection in early local stages. Local control includes surgery and/or radiotherapy depending on site, stage, histology and response to chemotherapy. This guide provides recommendations for diagnosis, staging and treatment of this neoplasm.